Skip to main content
Erschienen in: Infection 1/2013

01.02.2013 | Clinical and Epidemiological Study

Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy

verfasst von: M. Rapicetta, R. Monarca, L. A. Kondili, P. Chionne, E. Madonna, G. Madeddu, A. Soddu, A. Candido, S. Carbonara, M. S. Mura, G. Starnini, S. Babudieri

Erschienen in: Infection | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The prevalence of anti-hepatitis E virus (HEV) and anti-hepatitis A virus (HAV), as well as the possible links with socio-demographic and other viral risks factors, were evaluated in an inmates population.

Methods

The study population consisted of 973 consecutively recruited inmates of eight Italian prisons.

Results

The anti-HEV prevalence was 11.6 % (113/973). It increased significantly by age (χ2 for linear trend: p = 0.001) and was significantly higher among non-Italian compared to Italian inmates (15.3 vs. 10.7 %, respectively). Age >40 years [odds ratio (OR) 2.1; 95 % confidence interval (CI) 1.4–3.1], non-Italian citizenship (OR 1.8; 95 % CI 1.1–2.9) and anti-HIV seropositivity (OR 2.2; 95 % CI 1.2–4.2) were the only factors independently associated to anti-HEV positivity by logistic regression analysis. The overall anti-HAV prevalence was 86.4 %, and was significantly higher in non-Italian compared to Italian prisoners (92.6 vs. 84.9 %, respectively; p = 0.02). Age older than 40 years (OR 3.6; 95 % CI 2.2–5.9), <5 years formal education (OR 2.1; 95 % CI 1.3–3.2) and non-Italian nationality (OR 2.7; 95 % CI 1.5–4.8) were factors independently associated to anti-HAV positivity by the logistic regression analysis.

Conclusions

Compared to the general population, significantly higher anti-HEV and anti-HAV prevalences were observed in an inmates population in Italy. Old age and non-Italian nationality were factors independently related to both HEV and HAV exposures. This data suggest the important role of low socio-economic factors in the transmission of both infections in high-risk populations. The possible epidemiological and/or pathogenetic links between HEV and HIV exposures need to be studied further.
Literatur
1.
Zurück zum Zitat Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48:494–503.PubMedCrossRef Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48:494–503.PubMedCrossRef
3.
Zurück zum Zitat Preiss JC, Plentz A, Engelmann E, Schneider T, Jilg W, Zeitz M, et al. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection. 2006;34:173–5.PubMedCrossRef Preiss JC, Plentz A, Engelmann E, Schneider T, Jilg W, Zeitz M, et al. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection. 2006;34:173–5.PubMedCrossRef
4.
Zurück zum Zitat Pfefferle S, Frickmann H, Gabriel M, Schmitz N, Günther S, Schmidt-Chanasit J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2011;40:451–4. doi:10.1007/s15010-011-0220-7 PubMedCrossRef Pfefferle S, Frickmann H, Gabriel M, Schmitz N, Günther S, Schmidt-Chanasit J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2011;40:451–4. doi:10.​1007/​s15010-011-0220-7 PubMedCrossRef
5.
Zurück zum Zitat Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, et al. Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol. 2010;47:89–92.PubMedCrossRef Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, et al. Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol. 2010;47:89–92.PubMedCrossRef
6.
Zurück zum Zitat Friestad C. Socio-economic status and health in a marginalized group: the role of subjective social status among prison inmates. Eur J Public Health. 2010;20:653–8.PubMedCrossRef Friestad C. Socio-economic status and health in a marginalized group: the role of subjective social status among prison inmates. Eur J Public Health. 2010;20:653–8.PubMedCrossRef
7.
Zurück zum Zitat Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007;22:80–5.PubMedCrossRef Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007;22:80–5.PubMedCrossRef
8.
Zurück zum Zitat Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis. 2008;14:1353–9.PubMed Badiaga S, Raoult D, Brouqui P. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis. 2008;14:1353–9.PubMed
9.
Zurück zum Zitat Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7.PubMedCrossRef Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7.PubMedCrossRef
10.
Zurück zum Zitat Watkins RE, Mak DB, Connelly C. Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons. BMC Public Health. 2009;9:385.PubMedCrossRef Watkins RE, Mak DB, Connelly C. Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons. BMC Public Health. 2009;9:385.PubMedCrossRef
11.
Zurück zum Zitat Lin CF, Twu SJ, Chen PH, Cheng JS, Wang JD. Prevalence and determinants of hepatitis B antigenemia in 15,007 inmates in Taiwan. J Epidemiol. 2010;20:231–6.PubMedCrossRef Lin CF, Twu SJ, Chen PH, Cheng JS, Wang JD. Prevalence and determinants of hepatitis B antigenemia in 15,007 inmates in Taiwan. J Epidemiol. 2010;20:231–6.PubMedCrossRef
12.
Zurück zum Zitat Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009;13:356–8.PubMedCrossRef Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009;13:356–8.PubMedCrossRef
13.
Zurück zum Zitat Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010;14:e60–6.PubMedCrossRef Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010;14:e60–6.PubMedCrossRef
14.
Zurück zum Zitat Whiteman D, McCall B, Falconer A. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. J Viral Hepat. 1998;5:277–83.PubMedCrossRef Whiteman D, McCall B, Falconer A. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. J Viral Hepat. 1998;5:277–83.PubMedCrossRef
15.
Zurück zum Zitat Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine. 2004;22:2578–85.PubMedCrossRef Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine. 2004;22:2578–85.PubMedCrossRef
16.
Zurück zum Zitat Obriadina A, Meng JH, Ulanova T, Trinta K, Burkov A, Fields HA, et al. A new enzyme immunoassay for the detection of antibody to hepatitis E virus. J Gastroenterol Hepatol. 2002;17:S360–4.PubMedCrossRef Obriadina A, Meng JH, Ulanova T, Trinta K, Burkov A, Fields HA, et al. A new enzyme immunoassay for the detection of antibody to hepatitis E virus. J Gastroenterol Hepatol. 2002;17:S360–4.PubMedCrossRef
17.
Zurück zum Zitat Ferguson M, Walker D, Mast E, Fields H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals. 2002;30:43–8.PubMedCrossRef Ferguson M, Walker D, Mast E, Fields H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals. 2002;30:43–8.PubMedCrossRef
18.
Zurück zum Zitat Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368–75.PubMedCrossRef Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368–75.PubMedCrossRef
19.
Zurück zum Zitat Borgen K, Herremans T, Duizer E, Vennema H, Rutjes S, Bosman A, et al. Non-travel related hepatitis E virus genotype 3 infections in the Netherlands; a case series 2004–2006. BMC Infect Dis. 2008;8:61. doi:10.1186/1471-2334-8-61.PubMedCrossRef Borgen K, Herremans T, Duizer E, Vennema H, Rutjes S, Bosman A, et al. Non-travel related hepatitis E virus genotype 3 infections in the Netherlands; a case series 2004–2006. BMC Infect Dis. 2008;8:61. doi:10.​1186/​1471-2334-8-61.PubMedCrossRef
20.
Zurück zum Zitat Lewis HC, Wichmann O, Duizer E. Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect. 2010;138:145–66.PubMedCrossRef Lewis HC, Wichmann O, Duizer E. Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect. 2010;138:145–66.PubMedCrossRef
21.
Zurück zum Zitat FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Viral Hepatitis Prevention Board (VHPB): Conference Report. Vaccine. 2010;28:583–8.PubMedCrossRef FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Viral Hepatitis Prevention Board (VHPB): Conference Report. Vaccine. 2010;28:583–8.PubMedCrossRef
22.
Zurück zum Zitat Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis. 2010;51:e24–7.PubMedCrossRef Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis. 2010;51:e24–7.PubMedCrossRef
23.
Zurück zum Zitat Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res. 2011;161:84–92.PubMedCrossRef Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res. 2011;161:84–92.PubMedCrossRef
24.
Zurück zum Zitat Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jäger S, Sander M, et al. Systematic screening for novel, serologically reactive hepatitis E virus epitopes. Virol J. 2012;9:28–36.PubMedCrossRef Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jäger S, Sander M, et al. Systematic screening for novel, serologically reactive hepatitis E virus epitopes. Virol J. 2012;9:28–36.PubMedCrossRef
25.
Zurück zum Zitat Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D et al. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One. 2011;6:e21150.CrossRef Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D et al. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One. 2011;6:e21150.CrossRef
26.
Zurück zum Zitat Romanò L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol. 2011;54:34–40.PubMedCrossRef Romanò L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol. 2011;54:34–40.PubMedCrossRef
27.
Zurück zum Zitat Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. Study Group of Hepatitis E. J Med Virol. 1994;42:318–20.PubMedCrossRef Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. Study Group of Hepatitis E. J Med Virol. 1994;42:318–20.PubMedCrossRef
28.
Zurück zum Zitat Coppola RC, Masia G. Seroprevalence and epidemiological features of hepatitis E virus infection in Italy. In: Rizzetto M, Purcell RH, Jerin J, Verme G, editors. Viral hepatitis and liver disease. Torino: Minerva; 1997. p. 609–11. Coppola RC, Masia G. Seroprevalence and epidemiological features of hepatitis E virus infection in Italy. In: Rizzetto M, Purcell RH, Jerin J, Verme G, editors. Viral hepatitis and liver disease. Torino: Minerva; 1997. p. 609–11.
29.
Zurück zum Zitat Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat. 1996;3:197–202.PubMedCrossRef Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat. 1996;3:197–202.PubMedCrossRef
30.
Zurück zum Zitat Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, et al. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. J Med Virol. 1999;58:49–53.PubMedCrossRef Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, et al. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. J Med Virol. 1999;58:49–53.PubMedCrossRef
31.
Zurück zum Zitat Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999;6:53–7.PubMedCrossRef Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999;6:53–7.PubMedCrossRef
32.
Zurück zum Zitat Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.PubMedCrossRef Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.PubMedCrossRef
33.
Zurück zum Zitat Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KEA, Kovari H, et al. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074–8.PubMedCrossRef Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KEA, Kovari H, et al. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074–8.PubMedCrossRef
34.
Zurück zum Zitat Kondili LA, Chionne P, Porcaro A, Madonna E, Taffon S, Resuli B, et al. Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case–control study in Albania. Epidemiol Infect. 2006;134:95–101.PubMedCrossRef Kondili LA, Chionne P, Porcaro A, Madonna E, Taffon S, Resuli B, et al. Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case–control study in Albania. Epidemiol Infect. 2006;134:95–101.PubMedCrossRef
35.
Zurück zum Zitat Sagnelli E, Stroffolini T, Almasio P, Mele A, Coppola N, Ferrigno L, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat. 2006;13:67–71.PubMedCrossRef Sagnelli E, Stroffolini T, Almasio P, Mele A, Coppola N, Ferrigno L, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat. 2006;13:67–71.PubMedCrossRef
36.
Zurück zum Zitat Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol. 2008;23:45–53.PubMedCrossRef Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol. 2008;23:45–53.PubMedCrossRef
37.
Zurück zum Zitat Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, et al. Hepatitis A seroprevalence in Tuscany, Italy. Euro Surveill. 2009;14. pii: 19146. Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, et al. Hepatitis A seroprevalence in Tuscany, Italy. Euro Surveill. 2009;14. pii: 19146.
38.
Zurück zum Zitat Taffon S, Bidini G, Vichi F, Corti G, Genovese D, Kondili LA, et al. A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. J Clin Virol. 2011;50:142–7.PubMedCrossRef Taffon S, Bidini G, Vichi F, Corti G, Genovese D, Kondili LA, et al. A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. J Clin Virol. 2011;50:142–7.PubMedCrossRef
39.
Zurück zum Zitat Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, et al. An outbreak of hepatitis A virus infection with a high case–fatality rate among injecting drug users. J Hepatol. 2005;43:958–64.PubMedCrossRef Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, et al. An outbreak of hepatitis A virus infection with a high case–fatality rate among injecting drug users. J Hepatol. 2005;43:958–64.PubMedCrossRef
Metadaten
Titel
Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy
verfasst von
M. Rapicetta
R. Monarca
L. A. Kondili
P. Chionne
E. Madonna
G. Madeddu
A. Soddu
A. Candido
S. Carbonara
M. S. Mura
G. Starnini
S. Babudieri
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 1/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0385-8

Weitere Artikel der Ausgabe 1/2013

Infection 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.